CST, 35005S, EHMT1 (E6Q8B) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying EHMT1. Validated for Western Blotting,Immunoprecipitation. Available in 2 sizes. Highly specific and rigorously validated in-house, EHMT1 (E6Q8B) Rabbit Monoclonal Antibody (CST #35005) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity EHMT1 (E6Q8B) Rabbit Monoclonal Antibody recognizes endogenous levels of total EHMT1 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala196 of human EHMT1 protein. Background Euchromatic histone-lysine N-methyltransferase 1 (EHMT1), also referred to as G9a-like protein 1 (GLP), is a histone methyltransferase that specifically mono- and dimethylates lysine 9 of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. EHMT1 is a member of a family of histone lysine methyltransferases that contain a conserved catalytic SET domain originally identified in Drosophila Su(var)3-9, enhancer of zeste and trithorax proteins (1). Although EHMT1 can homodimerize , it is typically found as a heterodimer with its paralog G9a, also known as EHMT2; together these proteins function as the major euchromatic histone H3 Lys9 mono- and dimethyltransferase, creating transcriptionally repressive marks that facilitate gene silencing (2,3). The EHMT1/G9a complex also contains Wiz, a zinc finger protein that is required for EHMT1/G9a heterodimerization and complex stability (4). Wiz contains two CtBP co-repressor binding sites, which mediate the association of EHMT1/G9a with the CtBP co-repressor complex (4). In addition, EHMT1 and G9a are components of other large transcriptional co-repressor complexes, such as those involving E2F6 and CDP/cut (5-7). EHMT1/G9a methylates several non-histone substrates, including DNMT1, CEBP/β, HDAC1 (8), and p53, specifically at lysine 373 (9). p53 Lys373 methylation was initially reported to inhibit p53 activity, suggesting that EHMT1/G9a inhibitors could help treat p53-positive cancers (9). However, a more recent study found that human G9a activated p53 and that elevated G9a-p53 expression was associated with increased survival in lung cancer patients, suggesting that further studies are required to better understand the biological significance of this methylation event (10). Lastly, defects in EHMT1 are the cause of chromosome 9q subtelomeric deletion syndrome (9q-syndrome), also known as Kleefstra syndrome (KS). Common features of KS patients are moderate to severe intellectual disability, autism, epileptic seizures, microcephaly, and dysmorphic features (11). Alternate Names bA188C12.1; DEL9q34; DKFZp667M072; EHMT1; EHMT1 intronic transcript 1; EHMT1-IT1; Eu-HMTase1; euchromatic histone lysine methyltransferase 1; Euchromatic histone-lysine N-methyltransferase 1; EUHMTASE1; FLJ12879; FP13812; G9a like protein; G9a-like protein 1; GLP; GLP1; H3-K9-HMTase 5; Histone H3-K9 methyltransferase 5; Histone-lysine N-methyltransferase EHMT1; Histone-lysine N-methyltransferase, H3 lysine-9 specific 5; KIAA1876; KLEFS1; KMT1D; Lysine N-methyltransferase 1D Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 180 Source/Isotype: Rabbit IgG